Single-pill combination of amlodipine and valsartan in the management of hypertension

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 12, 2009, Pages 1979-1994

  Flack, John M ^a   Hilkert, Robert ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Amlodipine; Amlodipine valsartan; Angiotensin receptor blocker; Calcium channel blocker; Combination therapy; Hypertension; Valsartan

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS VALSARTAN; ANGIOTENSIN II; ATENOLOL; ATORVASTATIN; BENDROFLUMETHIAZIDE; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; CIMETIDINE; DIGOXIN; DOXAZOSIN; ENALAPRIL; FUROSEMIDE; GLIBENCLAMIDE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; INDOMETACIN; IRBESARTAN; LISINOPRIL; PERINDOPRIL; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; RAMIPRIL; VALSARTAN; WARFARIN;

ACUTE HEART INFARCTION; ANTIHYPERTENSIVE ACTIVITY; ANTIOXIDANT ACTIVITY; ARTHRALGIA; ATHEROSCLEROSIS; BACKACHE; BLOOD PRESSURE REGULATION; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INFLUENZA; MONOTHERAPY; NAUSEA; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; RECOMMENDED DRUG DOSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SYSTOLIC BLOOD PRESSURE; TABLET FORMULATION; THROMBOSIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VASODILATATION; VERTIGO;

AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DRUG COMBINATIONS; HUMANS; HYPERTENSION; PATIENT COMPLIANCE; TETRAZOLES; VALINE;

EID: 68149164589     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903120899     Document Type: Review

References (81)

1. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007;49:69-75
2. Cutler JA, Sorlie PD, Wolz M, et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008;52:818-827
3. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 2002;4:393-404
4. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906 (Pubitemid 41265663)
5. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860 (Pubitemid 34940824)
6. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252 (Pubitemid 37553153)
7. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003;163:525-541 (Pubitemid 36314340)
8. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007;115:2761-2788 (Pubitemid 46842793)
9. Garber AJ, Handelsman Y, Einhorn D, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract 2008;14:933-946
10. Mancia G, de Backer G, Dominiczak A, et al. 2007 ESH-ESC Guidelines for the management of arterial hypertension. Blood Press 2007;16:135-232
11. Gradman AH, Acevedo C. Evolving strategies for the use of combination therapy in hypertension. Curr Hypertens Rep 2002;4:343-349
12. Ferri C, Croce G, Desideri G. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine. Adv Ther 2008;25:300-320
13. Weir MR. Risk-based classification of hypertension and the role of combination therapy. J Clin Hypertens (Greenwich) 2008;10:4-12
14. Murdoch D, Heel RC. Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 1991;41:478-505
15. Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997;54:299-311
16. Mizuno Y, Jacob RF, Mason RP. Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease. Am J Hypertens 2008;21:1076-1085
17. Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol 2003;23:2155-2163 (Pubitemid 37532314)
18. Hayashi K, Wakino S, Sugano N, et al. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res 2007;100:342-353 (Pubitemid 46272406)
19. Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998;97:576-580 (Pubitemid 28090687)
20. Tulenko TN, Laury-Kleintop L, Walter MF, Mason RP. Cholesterol, calcium and atherosclerosis: is there a role for calcium channel blockers in atheroprotection? Int J Cardiol 1997;62:S55-66
21. Mason RP. Atheroprotective effects of long-acting dihydropyridine-type calcium channel blockers: evidence from clinical trials and basic scientific research. Cerebrovasc Dis 2003;16:11-17
22. Eickelberg O, Roth M, Block LH. Effects of amlodipine on gene expression and extracellular matrix formation in human vascular smooth muscle cells and fibroblasts: implications for vascular protection. Int J Cardiol 1997;62:S31-7 (Pubitemid 28068794)
23. Eickelberg O, Roth M, Mussmann R, et al. Calcium channel blockers activate the interleukin-6 gene via the transcription factors NF-IL6 and NF-kappaB in primary human vascular smooth muscle cells. Circulation 1999;99:2276-2282 (Pubitemid 29201134)
24. Garcha RS, Sever PS, Hughes AD. Mechanism of action of angiotensin II in human isolated subcutaneous resistance arteries. Br J Pharmacol 2001;134:188-196 (Pubitemid 32835482)
25. Timmermans PB. Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol 1999;15:26F-8F
26. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-912
27. Song JC, White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy 2000;20:130-139 (Pubitemid 30073833)
28. Thurmann PA. Valsartan: a novel angiotensin type 1 receptor antagonist. Expert Opin Pharmacother 2000;1:337-350
29. Arun KH, Kaul CL, Ramarao P. AT1 receptors and L-type calcium channels: functional coupling in supersensitivity to angiotensin II in diabetic rats. Cardiovasc Res 2005;65:374-386 (Pubitemid 40082479)
30. Hornig B, Landmesser U, Kohler C, et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001;103:799-805 (Pubitemid 32163876)
31. Antony I, Lerebours G, Nitenberg A. Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients. Circulation 1996;94:3115-3122 (Pubitemid 26427476)
32. Ceconi C, Fox KM, Remme WJ, et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007;73:237-246
33. Klingbeil AU, John S, Schneider MP, et al. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003;16:123-128 (Pubitemid 36143430)
34. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996;94:258-265
35. Burnier M, Brunner HR. Comparative antihypertensive effects of angiotensin II receptor antagonists. J Am Soc Nephrol 1999;10:S278-82 (Pubitemid 29159462)
36. Kalinowski L, Matys T, Chabielska E, et al. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 2002;40:521-527
37. Dielis AW, Smid M, Spronk HM, et al. Changes in fibrinolytic activity after angiotensin II receptor blockade in therapy-resistant hypertensive patients. J Thromb Haemost 2007;5:1509-1515 (Pubitemid 46965382)
38. Seeger H, Lippert C, Wallwiener D, Mueck AO. Valsartan and candesartan can inhibit deteriorating effects of angiotensin II on coronary endothelial function. J Renin Angiotensin Aldosterone Syst 2001;2:141-143 (Pubitemid 33686754)
39. Doumas MN, Douma SN, Petidis KM, et al. Different effects of losartan and moxonidine on endothelial function during sympathetic activation in essential hypertension. J Clin Hypertens (Greenwich) 2004;6:682-689
40. Nomura S, Shouzu A, Omoto S, et al. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb Res 2006;117:385-392 (Pubitemid 43197489)
41. Dandona P, Kumar V, Aljada A, et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab 2003;88:4496-4501 (Pubitemid 37153762)
42. Hernandez-Presa MA, Bustos C, Ortego M, et al. ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. Am J Pathol 1998;153:1825-1837 (Pubitemid 28550670)
43. Schmeisser A, Soehnlein O, Illmer T, et al. ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression. Biochem Biophys Res Commun 2004;325:532-540 (Pubitemid 39458027)
44. Manabe S, Okura T, Watanabe S, et al. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol 2005;46:735-739 (Pubitemid 44378243)
45. Ridker PM, Danielson E, Rifai N, Glynn RJ. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension 2006;48:73-79
46. Sironi L, Gelosa P, Guerrini U, et al. Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall. J Pharmacol Exp Ther 2004;311:989-995 (Pubitemid 39612703)
47. Willemsen JM, Westerink JW, Dallinga-Thie GM, et al. Angiotensin II type 1 receptor blockade improves hyperglycemia-induced endothelial dysfunction and reduces proinflammatory cytokine release from leukocytes. J Cardiovasc Pharmacol 2007;49:6-12
48. Yasunari K, Maeda K, Watanabe T, et al. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 2004;43:2116-2123 (Pubitemid 38686812)
49. de las Heras N, Aragoncillo P, Maeso R, et al. AT(1) receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits. Hypertension 1999;34:969-975
50. Li J, Hirose N, Kawamura M, Arai Y. Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits. Atherosclerosis 1999;143:315-326 (Pubitemid 29166912)
51. Haria M, Wagstaff AJ. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995;50:560-586
52. Reid JL, Meredith PA, Donnelly R, Elliott HL. Pharmacokinetics of calcium antagonists. J Cardiovasc Pharmacol 1988;12:S22-6
53. Martin U, Foreman MA, Travis JC, et al. Use of ACE inhibitors and ARBs in hypertensive women of childbearing age. J Clin Pharm Ther 2008;33:507-511
54. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997
55. Sever P, Dahlof B, Poulter N, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006;27:2982-2988 (Pubitemid 44950442)
56. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;292:2217-2225 (Pubitemid 39473159)
57. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675 (Pubitemid 33126822)
58. White HD, Aylward PE, Huang Z, et al. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation 2005;112:3391-3399 (Pubitemid 43739553)
59. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672-678 (Pubitemid 34851925)
60. Douglas JG, Agodoa L. ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial. Kidney Int 2003;63(suppl 83):S74-6
61. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031 (Pubitemid 38781102)
62. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363:2049-2051 (Pubitemid 38781107)
63. Flack JM, Duncan K, Ohmit SE, et al. Influence of albuminuria and glomerular filtration rate on blood pressure response to antihypertensive drug therapy. Vasc Health Risk Manag 2007;3:1029-1037
64. Nasser SA, Lai Z, O'Connor S, et al. Does earlier attainment of blood pressure goal translate into fewer cardiovascular events? Curr Hypertens Rep 2008;10:398-404
65. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007;29:563-580 (Pubitemid 47028551)
66. Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich) 2007;9:355-364
67. Destro M, Luckow A, Samson M, et al. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS study. J Am Soc Hypertens 2008;2:294-302
68. Poldermans D, Glazes R, Kargiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther 2007;29:279-289 (Pubitemid 46661857)
69. Flack JM, Calhoun DA, Satlin L, et al. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens 2009;23:479-489
70. Allemann Y, Fraile B, Lambert M, et al. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study. J Clin Hypertens (Greenwich) 2008;10:185-194
71. Sinkiewicz W, Glazer RD, Kavoliuniene A, et al. Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on valsartan monotherapy. Curr Med Res Opin 2009;25:315-324
72. Schrader J, Weisskopf M, Keeling L, Ferber P. The combination of amlodipine/ valsartan (5/160 mg) significantly reduces the incidence of peripheral edema versus amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg. J Hypertens 2008;26(Suppl 1):S478
73. Plosker GL, Robinson DM. Amlodipine/ Valsartan: fixed-dose combination in hypertension. Drugs 2008;68:373-381
74. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004;18:139-185 (Pubitemid 38425770)
75. Jamerson K, Bakris GL, Dahlof B, et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press 2007;16:80-86 (Pubitemid 47050368)
76. Jamerson KA, Bakris GL, Wun CC, et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens 2004;17:793-801
77. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-2428
78. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992;117:234-242
79. Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf 1999;21:23-33 (Pubitemid 29355511)
80. Weber MA. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension. J Hypertens Suppl 1997;15:S31-6
81. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995;75:793-795